<DOC>
	<DOCNO>NCT02018861</DOCNO>
	<brief_summary>Open-label , dose-escalation study subject previously treat B-cell malignancy find maximum tolerate dose ( MTD ) pharmacologic active dose PI3Kδ inhibitor , INCB050465 , monotherapy combination : itacitinib ( INCB039110 ) , JAK1 inhibitor ; rituximab ; rituximab , ifosfamide , carboplatin , etoposide . INCB050465 inhibit PI3Kδ , protein involved growth survival B-cell cancer cell .</brief_summary>
	<brief_title>A Phase 1/2 , Open-Label , Dose Escalation , Safety Tolerability Study INCB050465 Itacitinib ( INCB039110 ) Subjects With Previously Treated B-Cell Malignancies ( CITADEL-101 )</brief_title>
	<detailed_description />
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Etoposide phosphate</mesh_term>
	<mesh_term>Isophosphamide mustard</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Ifosfamide</mesh_term>
	<criteria>Aged 18 year old , lymphoid malignancy Bcell origin include : 1 . Indolent / aggressive Bcell nonHodgkin 's lymphoma ( NHL ) EXCLUDING : Burkitt 's lymphoma precursor B lymphoblastic leukemia/lymphoma INCLUDING : nonHodgkin 's B cell malignancy chronic lymphocytic leukemia ( CLL ) rare nonHodgkin 's B cell subtypes hairy cell leukemia , Waldenström macroglobulinemia ( WM ) , mantle cell leukemia ( MCL ) , transform NHL histology 2 . Hodgkin 's lymphoma ( HL ) Life expectancy 12 week longer Subject must receive ≥ 1 prior treatment regimen ( ) The subject must candidate potentially curative therapy include hematopoietic stem cell transplantation , except one standard therapy regimen combination may use prior transplantation per standard medical practice Has history brain metastasis , spinal cord compression ( unless treat , asymptomatic , stable recent image enrol expansion cohort ) , lymphoma involve central nervous system ( CNS ) Has Eastern Cooperative Oncology Group ( ECOG ) performance status ≥ 3 ( ≥ 2 dose escalation ) Received allogeneic hematopoietic stem cell transplant within last 6 month , active graft versus host disease ( GVHD ) follow allogeneic transplant , currently receive immunosuppressive therapy follow allogeneic transplant Received autologous hematopoietic stem cell transplant within last 3 month Inadequate marrow reserve assess hematologic laboratory parameter Inadequate renal liver function Known HIV infection , hepatitis B virus ( HBV ) hepatitis C virus ( HCV ) viremia risk HBV reactivation</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>